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In 1951 (1) we first reported on the use of Diasone, a substituted diamino-
diphenylsulfone, in the treatment of thirteen patients with dermatitis herpeti-
formis. Notwithstanding good results shown then, this form of therapy did not
become popular. Two reasons probably accounted for the poor reception of
this agent for Duhring's disease. There already was in use for a relatively short
time the best remedy for this dermatosis yet made available; and the stress we
placed on the inherent anemia-inducing properties of the sulfone group of drugs.
Besides, our report was perhaps a bit too conservative and was not sufficiently
bold in setting forth the effectiveness of these newer remedies. Even though
sulfapyridine was and remains the outstanding remedy for this one member of
the bullous group, inevitably there were a few subjects whose eruption resisted
this sulfonamide and some who became intolerant of it.
Since our first report on the use of Diasone, we were able to observe fourteen
more patients with dermatitis herpetiformis. Of these only two received another
sulfone, Promacetin, and the remainder the original drug. Of the first thirteen
subjects reported on in our first communication, five were observed for at least
five years. It would seem desirable to recount our further experience with these
five patients and the fourteen newer ones.
The five followed for at least five years continued to have more or less complete
relief from their ailment. All had at one time or another relapsed when they
discontinued their medicine. They could detect recurrence of symptoms after
going five to ten days without treatment. From time to time it became necessary
to increase a maintenance dose to prevent partial recrudescence. Usually adding
one or two tablets, 0.33 or 0.66 gram, to the maintenance dose almost always is
sufficient to recontrol an outbreak. The average dose to suppress symptoms in
these five patients is two tablets daily (0.66 gm.). One tablet suffices for one
patient, two tablets for three and three tablets for the filth patient. The originally
induced anemia spontaneously disappeared without administration of iron. The
maintenance dose is characteristic for each patient and when an increase becomes
necessary at any time this is almost always for only a short time. There were no
apparent untoward effects from long-continued use of Diasone.
We now have observed fourteen more patients with dermatitis herptiformis
since the last report. Of these twelve had treatment with Diasone. There were
few substantial differences between their responses and that of the original
group. One patient developed moderate gastrointestinal disturbances, nausea
and retching, while he was taking three tablets a day. The drug was stopped
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temporarily for several days. His treatment was started again with one tablet
daily and the dose increased gradually. He was able to take two tablets a day,
but began having gastrointestinal symptoms again when the dose rose to three
tablets. Two tablets, however, were insufficient to suppress all his skin symptoms,
though they were distinctly improved. The Diasone therapy was supplemented
with 50 mg. sulfapyridine, and with this combination the skin became free of
eruption and itching.
Another man was unable to tolerate even one tablet a day. He developed gas-
trointestinal disturbances with headache. On three occasions when treatment
with Diasone was attempted he promptly developed the same untoward effects.
He was the only one unable to continue with the drug.
The other ten patients for the most part had complete relief with two tablets
of Diasone a day. Two required three tablets and one man had complete remis-
sion with only one tablet a day. Most of the patients who were followed for a
sufficiently long time were found to vary somewhat in the amount of therapy
needed to keep them comfortable. At unpredictable intervals symptoms emerged
requiring an increased dosage to suppress them. Usually after a breif period the
patients could return to their ordinary maintenance dose.
Two patients were treated with Promacetin (acetosulfone). Their response to
this drug was as good as the others to Diasone. Both the hemoglobin and red
cell counts dropped initially, but regained most of their losses within six weeks.
Both patients required a daily dose of three grams for a maintenance dose. As
with all other effective drugs for dermatitis herpetiformis, treatment had to be
continued to prevent relapse.
From our brief observations with Promacetin it seems there is little choice
between this drug and Diasone. The latter, however, is more effective in a smaller
dosage, and presumably would therefore be safer. Final opinion on this would
require pharmacological experiment and knowledge we cannot bring to bear on
the problem.
The effectiveness of sulfapyridine and the sulfone drugs in the treatment of
Duhring's disease bespeaks an infecious basis for this dermatosis. On the other
hand, most microorganisms exposed for some time to an effective agent, but not
killed outright, develop resistance to and tolerance for the medicament, though
there are exceptions. If such living forms are, through some means, responsible
for the disease, they continue to be sensitive to all the effective drugs.
The introduction of sulfapyridine constituted a big advance in the treatment
of dermatitis herpetiformis. We are provided with a factor of safety in having
more than one drug available to combat this chronic ailment. This is especially
so in view of the not insignificant number of patients who are intolerant of
sulfapyridine either immediately or on prolonged use. Considering the low
toxicity of the sulfone group of drugs this circumstance of multiple choices is
particularly fortunate.
SUMMARY
The sulfone drugs have now been used for seven years in a total of twenty-
seven patients with dermatitis herpetiformis. Of this number, two patients
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received Promacetin and the rest were given Diasone. Both drugs are effective,
Diasone in smaller doses than Promacetin. Both show low toxicity and are wel-
come alternatives to sulfapyridine, either when the latter is not tolerated or
effective, or as initial treatment. Like su]fapyridine, to be effective the sulfone
drugs must continue to be exhibited to prevent relapse and remain effective
without developing in the patient resistance or tolerance.
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